Works matching DE "FINGOLIMOD"

Results: 665

Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Report and Literature Review.

Published in:

Neurology India, 2023, v. 71, n. 3, p. 546, doi. 10.4103/0028-3886.378695

By:

Mozhdehipanah, Hossein;
Safdarian, Farshid;
Paybast, Sepideh

Publication type:

Article

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Published in:

Veterinary & Comparative Oncology, 2017, v. 15, n. 3, p. 1115, doi. 10.1111/vco.12221

By:

Mani, R.;
Yan, R.;
Mo, X.;
Chen, C.‐S.;
Phelps, M. A.;
Klisovic, R.;
Byrd, J. C.;
Kisseberth, W. C.;
London, C. A.;
Muthusamy, N.

Publication type:

Article

Fingolimod affects gene expression profile associated with LPS-induced memory impairment.

Published in:

Experimental Brain Research, 2014, v. 232, n. 11, p. 3687, doi. 10.1007/s00221-014-4052-4

By:

Omidbakhsh, Rana;
Rajabli, Banafshe;
Nasoohi, Sanaz;
Khallaghi, Behzad;
Mohamed, Zahurin;
Naidu, Murali;
Ahmadiani, Abolhassan;
Dargahi, Leila

Publication type:

Article

Fingolimod ameliorates acetic acid‐induced ulcerative colitis: An insight into its modulatory impact on pro/anti‐inflammatory cytokines and AKT/mTOR signalling.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2022, v. 130, n. 5, p. 569, doi. 10.1111/bcpt.13720

By:

Makled, Mirhan N.;
Serrya, Marwa S.;
El‐Sheakh, Ahmed R.

Publication type:

Article

The Sphingosine 1‐Phosphate Analogue FTY720 Alleviates Seizure‐induced Overexpression of P‐Glycoprotein in Rat Hippocampus.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2018, v. 123, n. 1, p. 14, doi. 10.1111/bcpt.12973

By:

Gao, Fei;
Gao, Ying;
Meng, Fangling;
Yang, Chunmei;
Fu, Jiangfeng;
Li, Yajun

Publication type:

Article

Adverse Effect Profile of Topical Ocular Administration of Fingolimod for Treatment of Dry Eye Disease.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2017, v. 120, n. 4, p. 398, doi. 10.1111/bcpt.12717

By:

Xiao, Weibao;
Sun, Li;
Zhang, Nan;
Ye, Wen

Publication type:

Article

Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients with Fingolimod Treatment.

Published in:

Turkish Journal of Immunology, 2019, v. 7, n. 1, p. 31, doi. 10.25002/tji.2019.1035

By:

SEDAGHAT, Nahid;
MOTEDAYYEN, Hossein;
ALSAHEBFOSOUL, Fereshteh;
ETEMADIFAR, Masood;
OSTADI, Vajihe;
KIANPOUR, Fariborz;
AKBARI, Mojtaba;
VESTRI, Elettra;
ZARKESH Esfahani, Seyed Hamid

Publication type:

Article

The effect of fingolimod treatment on peripheral blood cell immunophenotypes in patients with multiple sclerosis.

Published in:

Turkish Journal of Immunology, 2016, v. 4, p. 77

By:

Ulusoy, Canan;
Yılmaz, Vuslat;
Tüzün, Erdem;
Adın Çınar, Suzan;
Akçay, Halil İbrahim;
Gunduz, Tuncay;
Eraksoy, Mefküre;
Kürtüncü, Murat;
Türkoğlu, Recai;
Altunrende, Burcu;
Çalışkan, Zeynep;
Kasap, Mithat

Publication type:

Article

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.

Published in:

Annals of Clinical & Translational Neurology, 2020, v. 7, n. 9, p. 1466, doi. 10.1002/acn3.51111

By:

Vollmer, Brandi L.;
Nair, Kavita;
Sillau, Stefan;
Corboy, John R.;
Vollmer, Timothy;
Alvarez, Enrique

Publication type:

Article

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.

Published in:

Annals of Clinical & Translational Neurology, 2019, v. 6, n. 2, p. 252, doi. 10.1002/acn3.700

By:

Vollmer, Brandi L.;
Nair, Kavita V.;
Sillau, Stefan;
Corboy, John R.;
Vollmer, Timothy;
Alvarez, Enrique

Publication type:

Article

Fingolimod treatment promotes regulatory phenotype and function of B cells.

Published in:

Annals of Clinical & Translational Neurology, 2015, v. 2, n. 2, p. 119, doi. 10.1002/acn3.155

By:

Grützke, Berit;
Hucke, Stephanie;
Gross, Catharina C.;
Herold, Martin V. B.;
Posevitz‐Fejfar, Anita;
Wildemann, Brigitte T.;
Kieseier, Bernd C.;
Dehmel, Thomas;
Wiendl, Heinz;
Klotz, Luisa

Publication type:

Article

Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination.

Published in:

Clinical & Translational Immunology, 2023, v. 12, n. 12, p. 1, doi. 10.1002/cti2.1480

By:

Robichon, Katharina;
Bibi, Rabia;
Kiernan, Mackenzie;
Denny, Lisa;
Prisinzano, Thomas E;
Kivell, Bronwyn M;
La Flamme, Anne Camille

Publication type:

Article

Pre-existing parasympathetic dominance seems to cause persistent heart rate slowing after 6 months of fingolimod treatment in patients with multiple sclerosis.

Published in:

Clinical Autonomic Research, 2025, v. 35, n. 1, p. 59, doi. 10.1007/s10286-024-01073-w

By:

Hilz, Max J.;
Canavese, Francesca;
de Rojas-Leal, Carmen;
Lee, De-Hyung;
Linker, Ralf A.;
Wang, Ruihao

Publication type:

Article

Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment.

Published in:

Oncology Letters, 2022, v. 23, n. 4, p. N.PAG, doi. 10.3892/ol.2022.13231

By:

Tanaka, Yuko;
Okabe, Seiichi;
Ohyashiki, Kazuma;
Gotoh, Akihiko

Publication type:

Article

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod.

Published in:

Metabolites (2218-1989), 2023, v. 13, n. 3, p. 428, doi. 10.3390/metabo13030428

By:

Murgia, Federica;
Lorefice, Lorena;
Noto, Antonio;
Spada, Martina;
Frau, Jessica;
Fenu, Giuseppe;
Coghe, Giancarlo;
Gagliano, Antonella;
Atzori, Luigi;
Cocco, Eleonora

Publication type:

Article

Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis.

Published in:

Metabolites (2218-1989), 2021, v. 11, n. 12, p. 812, doi. 10.3390/metabo11120812

By:

Yoon, Naeun;
Jang, Ah-Kyung;
Seo, Yerim;
Jung, Byung Hwa

Publication type:

Article

Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage.

Published in:

Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.613103

By:

Diaz Diaz, Andrea C.;
Shearer, Jennifer A.;
Malone, Kyle;
Waeber, Christian

Publication type:

Article

Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells.

Published in:

Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00217

By:

Eken, Ahmet;
Yetkin, Mehmet Fatih;
Vural, Alperen;
Okus, Fatma Zehra;
Erdem, Serife;
Azizoglu, Zehra Busra;
Haliloglu, Yesim;
Cakir, Mustafa;
Turkoglu, Enes Mehmet;
Kilic, Omer;
Kara, Irfan;
Dönmez Altuntaş, Hamiyet;
Oukka, Mohamed;
Kutuk, Mehmet Serdar;
Mirza, Meral;
Canatan, Halit

Publication type:

Article

Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.

Published in:

Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02189

By:

Mike, Elise V.;
Makinde, Hadijat M.;
Der, Evan;
Stock, Ariel;
Gulinello, Maria;
Gadhvi, Gaurav T.;
Winter, Deborah R.;
Cuda, Carla M.;
Putterman, Chaim

Publication type:

Article

A Human Oral Fluid Assay for D- and L- Isomer Detection of Amphetamine and Methamphetamine Using Liquid-Liquid Extraction.

Published in:

Journal of Analytical Methods in Chemistry, 2022, v. 2022, p. 1, doi. 10.1155/2022/4819599

By:

Robbins, Brian;
Carpenter, Rob E.;
Long, Mary;
Perry, Jacob

Publication type:

Article

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.

Published in:

Case Reports in Neurological Medicine, 2014, p. 1, doi. 10.1155/2014/307872

By:

Killestein, J.;
Vennegoor, A.;
van Golde, A. E. L.;
Bourez, R. L. J. H.;
Wijlens, M. L. B.;
Wattjes, M. P.

Publication type:

Article

Intermittent Atrioventricular Block following Fingolimod Initiation.

Published in:

Case Reports in Neurological Medicine, 2014, p. 1, doi. 10.1155/2014/191305

By:

Gialafos, E.;
Gerakoulis, S.;
Grigoriou, A.;
Haina, V.;
Kilidireas, C.;
Stamboulis, E.;
Andreadou, E.

Publication type:

Article

Fingolimod and melanoma risk: is there sufficient evidence?

Published in:

Clinical & Experimental Dermatology, 2017, v. 42, n. 4, p. 427, doi. 10.1111/ced.13066

By:

Filoni, A.;
Lospalluti, L.;
Giudice, G.;
Bonamonte, D.;
Vestita, M.

Publication type:

Article

Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.

Published in:

Clinical & Experimental Dermatology, 2016, v. 41, n. 4, p. 433, doi. 10.1111/ced.12770

By:

Haebich, G.;
Mughal, A.;
Tofazzal, N.

Publication type:

Article

Assessment of clinician adherence to Fingolimod instructions and its effect on patient safety.

Published in:

Neurosciences, 2024, v. 29, n. 3, p. 184, doi. 10.17712/nsj.2024.3.20240040

By:

Alhubaishi, Alaa A.;
Alsharekh, Lolwa M.;
Almoharb, Haya F.;
Alqarni, Faisal A.;
Alqahtani, Abdalhadi M.;
Alghazwni, Mohammed K.;
Alfuraydi, Modhi A.;
Alsadi, Abdulmajed Z.;
Altalhi, Raad Y.;
Almutairi, Tariq M.;
Alshehri, Ghadah H.

Publication type:

Article

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.

Published in:

Neurosciences, 2018, v. 23, n. 2, p. 129, doi. 10.17712/nsj.2018.2.20170434

By:

Ouspid, Elham;
Razazian, Nazanin;
Moghadasi, Abdorreza N.;
Moradian, Nasrin;
Afshari, Daryoush;
Bostani, Arash;
Sariaslani, Payam;
Ansarian, Atefeh

Publication type:

Article

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.

Published in:

Drug, Healthcare & Patient Safety, 2013, v. 5, p. 37, doi. 10.2147/DHPS.S28822

By:

Thöne, Jan;
Ellrichmann, Gisa

Publication type:

Article

Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells.

Published in:

2020

By:

Perla, Alexandre S.;
Fratini, Lívia;
Cardoso, Paula S.;
de Farias, Caroline Brunetto;
da Cunha Jaeger, Mariane;
Roesler, Rafael

Publication type:

Report

Integrating Rehabilomics into the Multi-Omics Approach in the Management of Multiple Sclerosis: The Way for Precision Medicine?

Published in:

Genes, 2023, v. 14, n. 1, p. 63, doi. 10.3390/genes14010063

By:

Bonnechère, Bruno

Publication type:

Article

FTY720 Suppresses Liver Tumor Growth and Metastasis by Reducing Circulating Regulating T Cells and Enhancing the Anti-Tumor Effect of Rapamycin.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 4743, doi. 10.2147/OTT.S234394

By:

Li, Chang Xian;
Yang, Xin Xiang;
Wang, Hong Wei;
Li, Xiang Cheng;
Ng, Kevin Tak-Pan;
Lo, Chung Mau;
Man, Kwan

Publication type:

Article

CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients.

Published in:

2022

By:

Karaaslan, Zerrin;
Kurtuncu, Murat;
Akcay, Halil İbrahim;
Gunduz, Tuncay;
Altunrende, Burcu;
Turkoglu, Recai;
Eraksoy, Mefkure;
Ulusoy, Canan;
Yilmaz, Vuslat;
Tüzün, Erdem

Publication type:

Letter

Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting.

Published in:

European Neurology, 2021, v. 84, n. 3, p. 200, doi. 10.1159/000514828

By:

Uzunköprü, Cihat;
Beckmann, Yesim;
Türe, Sabiha

Publication type:

Article

Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study.

Published in:

European Neurology, 2017, v. 77, n. 1/2, p. 47, doi. 10.1159/000451077

By:

Moreau, Thibault;
Bungener, Catherine;
Heinzlef, Olivier;
Suchet, Laurent;
Borgel, Florent;
Bourdeix, Isabelle;
Meite, Mohamed;
Rerat, Karin;
Chouette, Isabelle

Publication type:

Article

Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade.

Published in:

European Neurology, 2016, v. 75, n. 5/6, p. 274, doi. 10.1159/000446580

By:

Ribes García, Sara;
Gómez-Pajares, Fernando;
albelda Puig, Carmen;
García Herrera, José Luis;
Casanova Estruch, Bonaventura

Publication type:

Article

Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab.

Published in:

European Neurology, 2015, v. 73, n. 1/2, p. 57, doi. 10.1159/000365968

By:

Bianco, assunta;
Patanella, agata Katia;
Nociti, Viviana;
Marti, alessandro;
Frisullo, Giovanni;
Plantone, Domenico;
De Fino, Chiara;
Fetta, anna;
Batocchi, anna Paola;
Rossini, Paolo Maria;
Mirabella, Massimiliano

Publication type:

Article

Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study.

Published in:

European Neurology, 2014, v. 72, n. 3/4, p. 173, doi. 10.1159/000361044

By:

Gajofatto, alberto;
Bianchi, Maria Rachele;
Deotto, Luciano;
Benedetti, Maria Donata

Publication type:

Article

A Stability-Indicating HPLC Method for the Determination of Fingolimod in Pharmaceutical Dosage Forms.

Published in:

Scientia Pharmaceutica, 2015, v. 83, n. 1, p. 85, doi. 10.3797/scipharm.1408-08

By:

SOURI, Effat;
ZARGARPOOR, Mohammad;
MOTTAGHI, Siavash;
AHMADKHANIHA, Reza;
KEBRIAEEZADEH, Abbas

Publication type:

Article

Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.

Published in:

PLoS ONE, 2018, v. 13, n. 3, p. 1, doi. 10.1371/journal.pone.0193986

By:

Koda, Toru;
Namba, Akiko;
Nakatsuji, Yuji;
Niino, Masaaki;
Miyazaki, Yusei;
Sugimoto, Tomoyuki;
Kinoshita, Makoto;
Takata, Kazushiro;
Yamashita, Kazuya;
Shimizu, Mikito;
Fukazawa, Toshiyuki;
Kumanogoh, Atsushi;
Mochizuki, Hideki;
Okuno, Tatsusada

Publication type:

Article

FTY720 Modulates Microglia Toward Anti-inflammatory Phenotype by Suppressing Autophagy via STAT1 Pathway.

Published in:

Cellular & Molecular Neurobiology, 2021, v. 41, n. 2, p. 353, doi. 10.1007/s10571-020-00856-9

By:

Hu, Zi-Wei;
Zhou, Luo-Qi;
Yang, Sheng;
Chen, Man;
Yu, Hai-Han;
Tao, Ran;
Wu, Long-Jun;
Wang, Wei;
Zhang, Qiang;
Qin, Chuan;
Tian, Dai-Shi

Publication type:

Article

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod.

Published in:

Frontiers in Cellular Neuroscience, 2022, v. 16, p. 1, doi. 10.3389/fncel.2022.918041

By:

Kihara, Yasuyuki;
Zhu, Yunjiao;
Jonnalagadda, Deepa;
Romanow, William;
Palmer, Carter;
Siddoway, Benjamin;
Rivera, Richard;
Dutta, Ranjan;
Trapp, Bruce D.;
Chun, Jerold

Publication type:

Article

Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?

Published in:

Journal of Neural Transmission, 2023, v. 130, n. 8, p. 1003, doi. 10.1007/s00702-023-02618-5

By:

Leßmann, Volkmar;
Kartalou, Georgia-Ioanna;
Endres, Thomas;
Pawlitzki, Marc;
Gottmann, Kurt

Publication type:

Article

Metabolic map of the antiviral drug podophyllotoxin provides insights into hepatotoxicity.

Published in:

Xenobiotica, 2021, v. 51, n. 9, p. 1047, doi. 10.1080/00498254.2021.1961920

By:

Sun, Dongxue;
Gao, Xiaoxia;
Wang, Qiao;
Krausz, Kristopher W.;
Fang, Zhongze;
Zhang, Youbo;
Xie, Cen;
Gonzalez, Frank J.

Publication type:

Article

Hematopoietic system: Piquing platelet production.

Published in:

Nature Medicine, 2013, v. 19, n. 1, p. 29, doi. 10.1038/nm.3068

By:

Basson, Michael

Publication type:

Article

FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.

Published in:

BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-783

By:

Zhaoyang Lu;
Jiabei Wang;
Tongsen Zheng;
Yingjian Liang;
Dalong Yin;
Ruipeng Song;
Tiemin Pei;
Shangha Pan;
Hongchi Jiang;
Lianxin Liu

Publication type:

Article

Combined Use of Magnesium Sulfate and Fingolimod for Antenatal Neuroprotection against Inflammation-Mediated Experimental Preterm Brain Injury in a Rat Model.

Published in:

Fetal & Pediatric Pathology, 2022, v. 41, n. 4, p. 603, doi. 10.1080/15513815.2021.1945174

By:

Yalcin, Serenat Eris;
Sezik, Mekin;
Yavuz, And;
Savran, Mehtap;
Asci, Halil;
Ozmen, Ozlem

Publication type:

Article

Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis.

Published in:

Pharmacotherapy, 2021, v. 41, n. 5, p. 440, doi. 10.1002/phar.2517

By:

Earla, Jagadeswara R.;
Hutton, George J.;
Thornton, Douglas J.;
Chen, Hua;
Johnson, Michael L.;
Aparasu, Rajender R.

Publication type:

Article

Fingolimod-Compassionate-use-Programm.

Published in:

Der Nervenarzt, 2012, v. 83, n. 12, p. 1575, doi. 10.1007/s00115-012-3612-8

By:

Haas, J.;
Linker, R.A.;
Hartung, H.P.;
Meergans, M.;
Ortler, S.;
Tracik, F.

Publication type:

Article

FTY720 (Fingolimod) als neue Therapiemöglichkeit der Multiplen Sklerose.

Published in:

Der Nervenarzt, 2007, v. 78, n. 10, p. 1200, doi. 10.1007/s00115-007-2298-9

By:

Klatt, J.;
Hartung, H.-P.;
Hohlfeld, R.

Publication type:

Article

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.

Published in:

Central European Journal of Immunology, 2015, v. 40, n. 3, p. 354, doi. 10.5114/ceji.2015.54599

By:

RUDNICKA, JULIA;
CZERWIEC, MICHAŁ;
GRYWALSKA, EWELINA;
SIWICKA-GIEROBA, DOROTA;
WALANKIEWICZ, MONIKA;
GRAFKA, AGNIESZKA;
ZGURSKI, MICHAŁ;
SURDACKA, AGATA;
BARTOSIK-PSUJEK, HALINA;
ROLIŃSKI, JACEK

Publication type:

Article

FTY720 Reduces the Biomass of Biofilms in Pseudomonas aeruginosa in a Dose-Dependent Manner.

Published in:

Antibiotics (2079-6382), 2024, v. 13, n. 7, p. 621, doi. 10.3390/antibiotics13070621

By:

Niazy, Abdurahman A.;
Lambarte, Rhodanne Nicole A.;
Sumague, Terrence S.;
Vigilla, Mary Grace B.;
Bin Shwish, Najla M.;
Kamalan, Ranan;
Daeab, Eid Khulaif;
Aljehani, Nami M.

Publication type:

Article